Discussing feelings, sharing insights, and talking about the future... On November 23, in the Party-Mass Activity Room of Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, 20 Party members sat together in a circle, each taking turns to express their thoughts and experiences on studying the spirit of the Sixth Plenary Session of the 19th CPC Central Committee. The atmosphere at the scene was fervent and enthusiastic, and everyone felt full of confidence about the future.

In the Party and Mass Activities Room of Hebei Guangxiang Pharmaceutical Co., Ltd., part of Shisi Pharmaceutical Group, Party members are studying the spirit of the Sixth Plenary Session of the 19th Central Committee of the Communist Party of China.

Meanwhile, the square in front of the raw-material receiving area at Hebei Guangxiang Pharmaceutical was bustling with activity. Forklifts were shuttling back and forth as 54 tons of caffeine raw material were being loaded onto trucks. Packed containers were ready to depart, each one set for shipment to a port. This batch of goods will arrive at ports in Germany and Thailand respectively in just over a month.
“Over the past few days, we have been diligently studying the spirit of the Sixth Plenary Session of the 19th CPC Central Committee. The session emphasized high-quality development and the comprehensive deepening of reform and opening-up, providing clear guidance and boosting our confidence in enterprise development. Focusing on core technologies, our company continues to step up its R&D and innovation efforts. New technologies and new products have become a powerful new driving force behind our company’s high-quality development,” said Cui Yongbin, Chairman of Hebei Guangxiang Pharmaceutical Co., Ltd. “The decision by our company to set up operations in the Bohai New Area of Cangzhou was also driven by the boundless business opportunities brought about by the coordinated development of the Beijing-Tianjin-Hebei region.”
Hebei Guangxiang Pharmaceutical was completed and put into operation in 2019 in the Bohai New Area of Cangzhou. It is a supporting project through which Shijiazhuang Fourth Pharmaceutical Group leverages the historical opportunity presented by the coordinated development of the Beijing-Tianjin-Hebei region to promote industrial transformation, strengthen and supplement supply chains, and accelerate the implementation of its “raw materials + finished products” strategic layout.
Cui Yongbin said that Hebei Guangxiang Pharmaceutical primarily focuses on the production of active pharmaceutical ingredients (APIs) such as caffeine, metronidazole, and theophylline. The company has developed more than 40 high-value-added APIs—including refined, serialized, and high-end products—as well as innovative API formulations. It holds 12 core patents, and 95% of its products are exported. Since the beginning of this year, Hebei Guangxiang Pharmaceutical has been actively promoting a dual-circulation strategy in both domestic and international markets. In the first three quarters, both production and sales have surged, with sales increasing by 209% quarter-on-quarter. In particular, in the third quarter, export volumes rose by over 300% compared to the previous quarter. The company expects its annual output value to reach 70 million tons, with an annual revenue exceeding 200 million U.S. dollars. Its main export destinations include European and American countries such as the United States, Germany, Canada, and Austria.
Stepping into Workshop 603—The Theophylline Synthesis Workshop—at Hebei Guangxiang Pharmaceutical, one finds no production personnel in sight—only three or four staff members seated in front of computer terminals in the control room. The production process flowchart for theophylline, detailing steps such as primary refining of crude tea, filtration, secondary refining of crude tea, and another round of filtration, is posted on the wall. The clean production environment, clear status indicators, and brightly lit operational equipment all convey a sense of the company’s standardized and meticulous management.
“Currently, our production process features a very high degree of intelligence and automation. In the international API market, what matters most—not just price—is quality and low carbon emissions,” said Cui Yongbin.
Dedicated efforts in innovation, quality, environmental protection, and cost control are the secret to Hebei Guangxiang Pharmaceutical’s success in conquering global markets.
The eight large characters “Green Pharmaceutical, Harmonious Coexistence” on the office building of Hebei Guangxiang Pharmaceutical are particularly eye-catching.
Construction is being expedited at the site of the second-phase project for the biochemical wastewater treatment system at Hebei Guangxiang Pharmaceutical’s factory premises.
“Going global with active pharmaceutical ingredients requires clean, low-carbon production as the right path forward. Green pharmaceutical manufacturing is our corporate development philosophy,” said Cui Yongbin. “Currently, the second phase of our wastewater treatment biochemical system—under construction—is expected to go into operation in February 2022. This project adopts the internationally advanced MBBR biofluidized bed technology, which can rapidly enhance the treatment capacity and efficiency of the reaction tanks and strengthen the system’s resilience to shocks. Once completed, the wastewater treatment capacity will double. The application of these green, low-carbon technologies and equipment will further unlock environmental protection and cost advantages.”
Hebei Guangxiang Pharmaceutical is also the first in the pharmaceutical industry to adopt advanced technologies such as high-temperature wet oxidation for reducing COD, MVR desalination, ozone catalytic oxidation, and biochemical treatment. Its COD emission standards are significantly lower than the national benchmarks.
Dr. Zhu Shujie, a chemist, is the Deputy General Manager of Hebei Guangxiang Pharmaceutical. “After studying the spirit of the Sixth Plenary Session of the 19th CPC Central Committee, I’ve been deeply moved. The plenary session emphasized advancing self-reliance and strength in science and technology. As a Party member and a young science and technology professional, I feel a profound sense of responsibility,” said Zhu Shujie.
“Technological quality is the core of enterprise development,” said Zhu Shujie. “Focusing on API production, we’ve continuously tackled technical challenges and optimized our processes. By leveraging microreaction technology and continuous crystallization technology, we’ve overcome numerous technical hurdles—including agglomeration—during API manufacturing. As a result, product quality has improved significantly, meeting the demands of overseas markets.”
“Our products leverage China’s leading crystal-form control technology, enabling us to precisely manage particle size and bulk density to meet the diverse needs of high-end customers in Europe and the U.S. At the same time, this technology significantly improves quality indicators such as flowability for substances like caffeine and metronidazole, giving our products a clear edge over competitors in the market,” said Zhu Shujie proudly. Since its launch in 2019, Hebei Guangxiang Pharmaceutical has successively obtained national GMP certification as well as international certifications including BRC, FSSC22000, KOSHER, and HALAL.
“Next, we will continue to step up our R&D efforts and develop more specialized active pharmaceutical ingredients, contributing our part to the high-quality development of our company and to the nation’s drive for scientific and technological self-reliance and strength,” said Zhu Shujie.
Emotion is conveyed through communication, and warmth flows freely in the “Learning Hall.” “We’ve made the spirit of the plenary session a key component of our Party branch’s ‘Three Meetings and One Class’ activities,” said Yang Huiling, Secretary of the Party Branch of Hebei Guangxiang Pharmaceutical. “We’re adopting a combination of collective study, self-study, and online-plus-offline approaches to ensure comprehensive learning from top to bottom. Right now, everyone is brimming with enthusiasm and is firmly putting the spirit of the plenary session into practice by driving high-quality development.”
“The company places great emphasis on leveraging the exemplary and leading role of Party members. We make full use of the Guangxiang Pharmaceutical WeChat group to organize Party class activities for all Party members and update learning materials in real time. Moving forward, we will transform the spirit of the plenary session into a powerful driving force for performing our duties effectively, uniting all employees as one cohesive team. By staying committed to our respective roles and demonstrating dedication and professionalism, we will make our due contributions to promoting industrial upgrading and high-quality development during the 14th Five-Year Plan period.” Guided by the spirit of the plenary session, Yang Huiling is brimming with confidence in the company’s future development.

(Reposted from Changcheng Net Jiyun)